Marc Therrien is a full professor in the Department of Pathology and Cell Biology at the Faculty of Medicine of the Université de Montréal and Chief Officer of IRIC.
His work on gene transcription control under Jacques Drouin at the Montreal Clinical Research Institute (IRCM) led to a PhD in biochemistry from UdeM in 1993.
He then completed a postdoctoral fellowship in molecular genetics with Gerald M. Rubin at the University of California, Berkeley, where he identified several novel components of the RAS-MAPK signaling pathway, whose deregulation is closely linked to the development of many cancers.
Returning to Montreal in 1999, he became a senior researcher at the IRCM. In 2003, he joined the Institute for Research in Immunology and Cancer (IRIC) at UdeM, of which he is a founding member, and became head of the Intracellular Signaling Research Unit. He also holds a Canada Research Chair in Intracellular Signaling.
In 2013, he was appointed Scientific Director of IRIC, a position he held for ten years. In 2024, he became Executive Director of the Institute, succeeding Michel Bouvier.
